Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Oramed Pharmaceuticals, Raises Price Target to $32

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Buy and raises the price target from $17 to $32.
byBenzinga Newsdesk
November 29, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Buy and raises the price target from $17 to $32.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0